The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2016 Sep 7

PMID 27597943

Citations 38

Authors

Sean P Kennedy

Jordan F Hastings

Jeremy Z R Han

David R Croucher

Affiliations

Soon will be listed here.

Abstract

Each member of the epidermal growth factor receptor (EGFR) family plays a key role in normal development, homeostasis, and a variety of pathophysiological conditions, most notably in cancer. According to the prevailing dogma, these four receptor tyrosine kinases (RTKs; EGFR, ERBB2, ERBB3, and ERBB4) function exclusively through the formation of homodimers and heterodimers within the EGFR family. These combinatorial receptor interactions are known to generate increased interactome diversity and therefore influence signaling output, subcellular localization and function of the heterodimer. This molecular plasticity is also thought to play a role in the development of resistance toward targeted cancer therapies aimed at these known oncogenes. Interestingly, many studies now challenge this dogma and suggest that the potential for EGFR family receptors to interact with more distantly related RTKs is much greater than currently appreciated. Here we discuss how the promiscuity of these oncogenic receptors may lead to the formation of many unexpected receptor pairings and the significant implications for the efficiency of many targeted cancer therapies.

Citing Articles

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

Synthetic approaches for novel fused pyrimidine derivatives: Design, structural characterization, antiviral, antitumor, and molecular docking evaluation.

Sefrji F, Alrefaei A, Imam M, Ashour G, Abualnaja M, Attar R Heliyon. 2024; 10(24):e40903.

PMID: 39720060 PMC: 11667641. DOI: 10.1016/j.heliyon.2024.e40903.

Spatial and signaling overlap of growth factor receptor systems at clathrin-coated sites.

Alfonzo-Mendez M, Strub M, Taraska J Mol Biol Cell. 2024; 35(11):ar138.

PMID: 39292879 PMC: 11617105. DOI: 10.1091/mbc.E24-05-0226.

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.

Mustafa M, Abbas K, Alam M, Habib S, Zulfareen , Hasan G Front Oncol. 2024; 14:1427802.

PMID: 39087024 PMC: 11288929. DOI: 10.3389/fonc.2024.1427802.

Crosstalk of growth factor receptors at plasma membrane clathrin-coated sites.

Alfonzo-Mendez M, Strub M, Taraska J bioRxiv. 2024; .

PMID: 38903101 PMC: 11188102. DOI: 10.1101/2024.05.16.594559.

References

Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R . The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992; 70(3):431-42. DOI: 10.1016/0092-8674(92)90167-b. View

Nolting M, Schneider-Merck T, Trepel M . Lapatinib. Recent Results Cancer Res. 2014; 201:125-43. DOI: 10.1007/978-3-642-54490-3_7. View

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

Landi L, Cappuzzo F . Experience with erlotinib in the treatment of non-small cell lung cancer. Ther Adv Respir Dis. 2015; 9(4):146-63. DOI: 10.1177/1753465815588053. View

Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2000; 103(2):211-25. DOI: 10.1016/s0092-8674(00)00114-8. View

Kumler I, Tuxen M, Nielsen D . A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2013; 40(2):259-70. DOI: 10.1016/j.ctrv.2013.09.002. View

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View

Sacco A, Worden F . Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther. 2016; 9:1927-43. PMC: 4831599. DOI: 10.2147/OTT.S93720. View

Levitzki A, Mishani E . Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 2006; 75:93-109. DOI: 10.1146/annurev.biochem.75.103004.142657. View

10.

Wallasch C, Weiss F, Niederfellner G, Jallal B, Issing W, Ullrich A . Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995; 14(17):4267-75. PMC: 394510. DOI: 10.1002/j.1460-2075.1995.tb00101.x. View

11.

Desbois-Mouthon C . The HER3/ErbB3 receptor: a promising target in cancer drug therapy. Gastroenterol Clin Biol. 2010; 34(4-5):255-9. DOI: 10.1016/j.gcb.2010.03.002. View

12.

Thery J, Spano J, Azria D, Raymond E, Penault Llorca F . Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer. 2014; 50(5):892-901. DOI: 10.1016/j.ejca.2014.01.003. View

13.

Huang X, Gao L, Wang S, McManaman J, Thor A, Yang X . Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010; 70(3):1204-14. DOI: 10.1158/0008-5472.CAN-09-3321. View

14.

Forde P, Ettinger D . Managing acquired resistance in EGFR-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2015; 13(8):528-32. View

15.

Kolch W, Pitt A . Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 2010; 10(9):618-29. DOI: 10.1038/nrc2900. View

16.

Riese 2nd D, van Raaij T, Plowman G, ANDREWS G, Stern D . The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol. 1995; 15(10):5770-6. PMC: 230829. DOI: 10.1128/MCB.15.10.5770. View

17.

Balana M, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau E . Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene. 2001; 20(1):34-47. DOI: 10.1038/sj.onc.1204050. View

18.

Gullick W . c-erbB-4/HER4: friend or foe?. J Pathol. 2003; 200(3):279-81. DOI: 10.1002/path.1335. View

19.

Westphal M, Meima L, Szonyi E, Lofgren J, Meissner H, Hamel W . Heregulins and the ErbB-2/3/4 receptors in gliomas. J Neurooncol. 1998; 35(3):335-46. DOI: 10.1023/a:1005837122181. View

20.

Creedon H, Byron A, Main J, Hayward L, Klinowska T, Brunton V . Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem Soc Trans. 2014; 42(4):822-30. DOI: 10.1042/BST20140109. View